Business
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three months ended March 31, 2026. Q1 2026 Financial
About this update from Scienture Holdings, Inc.
[{"type":"image","alt":"Scienture Holdings, Inc.","displaySize":"","headline":null,"caption":"Scienture Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":33,"url":"https://media.zenfs.com/en/globenewswire.com/0f6cc02a4da7ea464abfe1cb57925027"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HVe91D1EZWtbCkMx1Lfv7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ2/https://media.zenfs.com/en/globenewswire.com/0f6cc02a4da7ea464abfe1cb57925027","width":300,"height":33},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/HVe91D1EZWtbCkMx1Lfv7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ2/https://media.zenfs.com/en/globenewswire.com/0f6cc02a4da7ea464abfe1cb57925027","width":300,"height":33}},"lazy":false},{"type":"text","content":"COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three months ended March 31, 2026.","length":482,"tagName":"p"},{"type":"text","content":"Q1 2026 Financial Highlights Compared to Q1 2025:","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue increased to approximately $56 thousand for the three months ended March 31, 2026, compared to approximately $10 thousand in the prior-year three-month period, representing an increase of approximately 449% year-over-year, reflecting incremental product orders for ArbliTM in addition to the initial launch quantities ordered in the fourth quarter of 2025","length":363,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross profit increased substantially to approximately $54 thousand, compared to approximately $673 in the prior-year three-month period, representing an increase of approximately 7900% year-over-year, primarily as a result of the increase in ArbliTM product orders","length":264,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross margin expanded to approximately 95.6% for the three months ended March 31, 2026, compared to approximately 6.6% in the prior-year three-month period, also as a result of the increase i...